COMPANY

Alzamend Neuro

HQ: Atlanta, GA source · alzamend.com ↗ · Southeast

Keywords: neurology Alzheimer's disease bipolar disorder major depressive disorder Alzheimer Disease Bipolar I Disorder AL001

Location: Atlanta, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

May 11, 2026 Trial start Phase 1/Phase 2: A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bi source ↗
Jun 16, 2025 Raise Private placement: $5M (total, as published), announced Jun 16, 2025. Source: company release on GlobeNewswire. source ↗
May 9, 2025 Trial start Phase 1: A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects source ↗
Jul 5, 2023 Trial start Phase 1/Phase 2: Study in Subjects With Mild-to-Moderate Alzheimer's Dementia source ↗
May 4, 2022 Trial start Phase 1/Phase 2: Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects source ↗

2026-12 (ESTIMATED) · Phase 1/Phase 2 · A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder · NCT07540338
Mar 3, 2028 (ESTIMATED) · Phase 1/Phase 2 · Study in Subjects With Mild-to-Moderate Alzheimer's Dementia · NCT05834296

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $5.0M. Last 2 years.

Jun 16, 2025 Private placement: $5M (total, as published), announced Jun 16, 2025. Source: company release on GlobeNewswire. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05834296	Study in Subjects With Mild-to-Moderate Alzheimer's Dementia	Phase 1/Phase 2	Active, not recruiting	Jul 5, 2023	Mar 3, 2028 (estimated)
NCT06921590	A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects	Phase 1	Completed	May 9, 2025	Dec 15, 2025 (actual)
NCT07540338	A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder	Phase 1/Phase 2	Recruiting	May 11, 2026	2026-12 (estimated)
NCT05363293	Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects	Phase 1/Phase 2	Completed	May 4, 2022	Apr 14, 2023 (actual)